Ocular Hypertension Treatment Study (OHTS) (OHTS)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00000125 |
Recruitment Status :
Completed
First Posted : September 24, 1999
Results First Posted : March 19, 2015
Last Update Posted : June 2, 2020
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
To determine whether medical reduction of intraocular pressure prevents or delays the onset of glaucomatous visual field loss and/or optic disc damage in ocular hypertensive participants judged to be at moderate risk for developing open-angle glaucoma.
To produce natural history data to assist in identifying patients at most risk for developing open-angle glaucoma and those most likely to benefit from early medical treatment.
To quantify risk factors for developing open-angle glaucoma among ocular hypertensive individuals.
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Ocular Hypertension Glaucoma | Drug: Topical ocular hypotensive eye drops. | Phase 3 |

Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 1636 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Prevention |
Official Title: | Ocular Hypertension Treatment Study (OHTS) |
Actual Study Start Date : | February 1994 |
Actual Primary Completion Date : | June 2002 |
Actual Study Completion Date : | June 30, 2019 |

Arm | Intervention/treatment |
---|---|
No Intervention: Observation
Close Observation.
|
|
Treatment
Participants treated with commercially available topical ocular hypotensive eye drops.
|
Drug: Topical ocular hypotensive eye drops.
Topical ocular hypotensive eye drops. |
- Incidence of Primary Open-Angle Glaucoma in Hypotensive Patients [ Time Frame: 5 yrs (OHTS I, June 2002) and 13.0 yrs (completion of both phases of OHTS, March 2009) ]Comparison of the cumulative proportion of participants who develop primary open-angle glaucoma in the observation and medication groups.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 40 Years to 80 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00000125
Study Chair: | Michael A Kass, MD | Washington University Department of Ophthalmology and Visual Sciences |
Documents provided by Washington University School of Medicine:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Washington University School of Medicine |
ClinicalTrials.gov Identifier: | NCT00000125 |
Other Study ID Numbers: |
NEI-24 5U10EY009307-16 ( U.S. NIH Grant/Contract ) 5U10EY009341-14 ( U.S. NIH Grant/Contract ) |
First Posted: | September 24, 1999 Key Record Dates |
Results First Posted: | March 19, 2015 |
Last Update Posted: | June 2, 2020 |
Last Verified: | May 2020 |
Glaucoma Ocular Hypertension Hypertension Vascular Diseases Cardiovascular Diseases |
Eye Diseases Antihypertensive Agents Ophthalmic Solutions Pharmaceutical Solutions |